Chronic Airways Assessment Test (CAAT)
Chronic Airways Assessment Test: A unified tool for assessing chronic airway diseases
CAAT can now be used for assessing respiratory health status in people with asthma, not just COPD
A simple and standardized health status measure
A standardized, easy to administer, health status measure for use across obstructive lung diseases.
Structure and components of the CAAT
8-items assessing aspects of disease relevant to patients.
Development and validation
The COPD assessment test (CAT) and the Chronic Airways Test (CAAT) were developed by an interdisciplinary group of international experts with support from GSK.
CAT and CAAT activities are monitored by a supervisory council that includes independent experts, one of which is chair of the council.
CAT, COPD Assessment Test, CAAT, Chronic Airways Assessment Test and the CAT logo are trademarks of the GSK group of companies.
Implementation and resources
Scan the QR code for the CAAT User Guide.
Documents for download
Read more details at
Fecha de publicación
September 2025
Categorías asociadas al artículo
Noticias relacionadas
Using AI for COPD Diagnosis, Equity, Guideline Gaps: Alvar Agusti, MD, PhD
AI in COPD diagnosis can support case finding, spirometry interpretation and equity while GOLD 2026 highlights validation and guideline gaps.
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials
Astegolimab for COPD was evaluated in the ALIENTO and ARNASA trials to assess its efficacy and safety in patients with frequent exacerbations.
Maternal smoking and CC-16: implications for lung development and COPD across the lifespan
Maternal smoking and CC16 are linked to impaired lung development, lung function decline and emphysema progression, increasing lifelong COPD risk.
Concavity of the maximal expiratory flow–volume curve, and incidence of COPD and respiratory symptoms: a population-based cohort study
Expiratory flow-volume curve concavity predicts future respiratory symptoms but shows lower discriminatory accuracy for COPD incidence than FEV1/FVC.
Body Mass Index-related genetic factors and COPD imaging phenotypes
BMI genetic factors and COPD are associated with decreased emphysema and increased airway wall thickness across quantitative and visual imaging phenotypes
Key recommendations for primary care from the 2026 GOLD update
2026 GOLD update: key recommendations for primary care on COPD diagnosis, assessment, prevention, treatment, exacerbations and emerging technologies.
Imagen obtenida de la presentación